Miodesin | 2022 Miodesin positively modulates the immune response in endometrial and vaginal cells Rocha OC, Polonini HC, Marcucci MC, Vieira RP Molecules, 27(3), 782 This study investigated whether Miodesin (10 µg/mL = IC80; 200 µg/mL = IC50) could exert anti-inflammatory and anti-proliferative effects against Lipopolysaccharides stimulation in endometrial and Candida albicans vaginal cell lines. The study concludes that Miodesin presents beneficial effects in the context of endometriosis, positively affecting the inflammatory and proliferative response. Read more
FagronLab | 2022 Effectiveness of a new ultraviolet C disinfection system to inactivate airborne Coronavirus in different environmental conditions Marianni B, Polonini HC International Journal of Pharmaceutical Compounding, 26(5), 432-435 The aim of this study was to validate the efficacy of a new ultraviolet C light disinfection system in different environmental conditions. The device was effective in the neutralization of airborne particles containing coronavirus genus samples, presenting >99.99% of inactivation rate in an aerosolization test. Read more
DiluCap | 2022 Evaluation of the physical-chemical characteristics and biopharmaceutical performance of DiluCap: A complete line of excipients for hard-shell capsules Ferreira AO, Polonini HC International Journal of Pharmaceutical Compounding, 26(4), 283-291 The testing conducted for the DiluCap line of excipients showed that all products have suitable flow properties, hygroscopicity, biopharmaceutical performance, and stability; supporting the use of this line of excipients by the compounding pharmacies with proven functionality that saves time and guarantees efficacy and safety of hard-shell oral capsules formulations. Read more SEE PRODUCT
Syrspend SF | 2022 Doseerhomogeniteit van meer dan honderd SyrSpend® SF suspensies onderzocht na bewaren Dijkers E, Polonini HC, Ferreira AO Nederlands Platform voor Farmaceutisch Onderzoek The purpose of this study was to investigate the homogeneity and resuspendability of SyrSpend SF suspensions. HPLC analysis was performed for 104 different formulations with 89 unique active pharmaceutical ingredients . All samples in SyrSpend SF were compliant with the specifications set by the British Pharmacopoeia. Read more SEE PRODUCT
Cleoderm | 2022 Compatibility of personalized formulations in Cleoderm™. A skin rebalancing cream base for oily and sensitive skin Polonini HC, Marianni B, Taylor S, Zander C Cosmetics, 9(5), 92 In this bracketed study, benzoyl peroxide, cyproterone acetate, estriol, metronidazole, niacinamide, progesterone, retinoic acid, spironolactone, and tranexamic acid were evaluated for compatibility and stability in Cleoderm™. For most formulations, a beyond-use date (BUD) of 180 days was observed when stored at room temperature, except for retinoic acid (BUD 30 days). Read more SEE PRODUCT
Fagron Advanced Derma | 2022 Stability and formulation of Erlotinib in skin creams Nguyen D, Secretan PH, Cotteret C, Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S Molecules, 27(3), 1070 A method to prepare 0.2% oral erlotinib cream, without resorting to a pure active pharmaceutical ingredient, was developed. The proposed formulation is stable for at least 42 days at room temperature in Nourivan cream with antioxidant properties. Read more SEE PRODUCT
Pentravan | 2022 Ex-vivo study of the percutaneous absorption of a Tramadol formulation through feline inner pinna skin Sainte Beuve M, Espana B, Pin D, Prouillac C Research in Veterinary Science, 151, 57-63 This ex vivo study aimed to characterize the percutaneous absorption pharmacokinetics of tramadol 100mg/ml in Pentravan through feline inner pinna skin. The tramadol formulation was stable for three months at room temperature. Tramadol penetrated through the feline inner pinna skin, but considerable intra- and inter-individual variability in kinetics was observed. Read more SEE PRODUCT
TrichoConcept | 2022 Compatibility of different formulations in TrichoConcept™ vehicles for hair treatments Polonini HC, Taylor S, Zander C Scientia Pharmaceutica, 90(1), 16 This study assessed the beyond-use date (BUD) of seven APIs for topical use for alopecia in TrichoWash, TrichoCream, TrichoCond, and TrichoSol: All formulations presented a BUD of 6 months, except for latanoprost in TrichoCream and latanoprost in combination with minoxidil and finasteride in TrichoSol (BUD 3 months). Read more SEE PRODUCT
Fagron Advanced Derma | 2021 Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone single formulation in Fitalite™, Versatile™, or HRT Supreme Cream Base Polonini HC, Dijkers E, Ferreira AO, Zander C, Taylor S International Journal of Pharmaceutical Compounding, 25(4), 336-343 In this study, the beyond-use date of formulations containing estradiol, estriol, estrone, progesterone, and testosterone in combination, compounded with Fitalite, Versatile, and HRT Supreme Cream base was evaluated. A beyond-use date of 180 days was observed for all vehicles stored both at refrigerated and at room temperature. Read more SEE PRODUCT
Yuliv Collagen Drink | 2021 Beauty from within: A review of the science behind Yuliv™ Collagen Drink: An anti-aging nutraceutical Polonini HC, Dijkers E, Ferreira AO Journal of Cosmetics, Dermatological Sciences and Applications, 11(3), 263-278 In this article, theoretical scientific support for Yuliv Collagen Drink and its benefits on the skin is presented. Literature shows that its ingredients have the potential to improve hydration, and dermis collagen density. Other benefits observed include oxidative stress protection, immune system support, and reduction of fatigue, and skin inflammation. Read more